Fusion protein · Immune activation · developed by Werewolf Therapeutics
WTX-330 is an engineered prodrug form of the human cytokine interleukin-12, with IL-12 held inactive by a blockade element linked through a tumor protease-sensitive linker and a half-life extension domain. Proteolytic cleavage in the tumor microenvironment releases active IL-12, which promotes IFN-gamma secretion and activates CD8+ T-cells, CD4+ T-cells and natural killer cells. It is studied in advanced or metastatic solid tumors and non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06939283 | Phase 1/2 | Advanced or Metastatic Solid Tumors | Completed | HOWL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid TumorsNon-Hodgkin Lymphoma
See HOWL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HOWL catalysts and pipeline →